Acorai

Acorai is a Swedish medical device company founded in 2019, dedicated to improving heart failure management through advanced, non-invasive technologies. The company aims to develop cost-efficient solutions that assist healthcare professionals in providing personalized treatment for heart failure patients. Acorai's flagship product, the SAVE Sensor System, is a multi-sensor platform that non-invasively measures intracardiac and pulmonary artery pressures. This handheld device combines seismic, acoustic, visual, and electric sensors with proprietary machine learning algorithms. It offers accurate monitoring of cardiac pressures, traditionally requiring invasive procedures, and is designed for use in hospital or clinical settings. The technology has undergone extensive clinical testing, demonstrating strong correlations with invasive measurements, and has received FDA Breakthrough Device Designation in 2023. Acorai plans to enter the U.S. market by 2026, aiming to enhance heart failure care by reducing hospital readmissions and complications through continuous monitoring.

• Employees 20
• Founded 2019
• Total Funding $10959643